Should your practice add compounded weight management, peptide or hormone therapy?

A note on evidence, before anything else

This page makes its case from mechanism rather than from market statistics, deliberately. There are plenty of numbers circulating about the size of this category, most of them from vendors selling into it, and we would rather argue something you can check against your own schedule than quote a figure you cannot. The one piece of evidence that matters is in your own practice: count how many times in the last month a patient asked about weight management, hormone therapy or recovery, and what happened to those conversations.

What you would actually be adding

Non-controlled compounded preparations, prepared by a licensed pharmacy against a prescription written for a named patient. In practice that is medical weight management, peptide therapy, hormone therapy including testosterone replacement for patients who qualify, aesthetics, sexual health and general wellness.

Compounding is not a workaround. It is a regulated activity with its own framework: 503A pharmacies compound for an identified patient against a specific prescription, and 503B outsourcing facilities operate under FDA registration. What you are adding is a supply route, not a new standard of care.

Worth knowing: none of this is a controlled substance, so this category carries none of the electronic-prescribing burden that comes with Schedule II to V.

The four arguments that hold up

1. The patient is already yours

You have already paid to acquire them and they already trust you. A patient who asks about weight management and gets a referral elsewhere is a patient you spent money on and handed to someone else, often permanently, because the practice that starts a long-running program usually keeps the relationship.

2. Saying no does not end the conversation

It moves it somewhere with less supervision. The alternative to your practice is frequently a website with no evaluation, no follow-up and no licensed relationship. Clinicians who offer these categories often describe the decision less as a revenue move than as declining to leave their patients to the open internet.

3. It is recurring by nature

These are programs rather than single visits: evaluation, titration, follow-up and monitoring. That is more clinical contact than a one-time procedure, which is a commercial advantage and a clinical obligation at the same time. If you are not prepared to run the follow-up, this is not for you.

4. You keep control of your own pricing

You buy at the pharmacy's listed price plus a disclosed platform fee, and you decide what your patient pays. That spread is your practice's business and nobody else sets it.

What it costs you, honestly

What it does not cost you is inventory. The pharmacy dispenses and ships directly to the patient, so nothing is stocked, nothing expires on your shelf and you are not holding medication.

What you must have in place first

• A clinician licensed in the state the patient is in.
• A genuine provider-patient relationship, with an evaluation that is capable of concluding no.
• Your own clinical judgment about appropriateness, which no platform and no pharmacy can supply for you.
• The follow-up capacity these programs require.

A platform can route a prescription, compare pharmacies and keep the record. It cannot decide whether a therapy suits your patient, and you should be suspicious of anything that implies otherwise.

Who this does not suit

• A practice with no prescriber. That is a different structure, and the brands path is the right one.
• A practice without the capacity to follow patients over months.
• Anyone whose plan depends on a high prescribe rate. If a clinician declining would be a problem for the model, the model is wrong.

This article is general information rather than clinical or legal advice. What is appropriate for a given patient is a matter for the treating clinician.